Revenue (Tables)

3 Months Ended

Mar. 31, 2020

Risks and Uncertainties [Abstract]

Disaggregation of Revenue

The following table and description below shows the products from which the Company generated its revenue:

	Three Months Ended March 31,
Revenue by product (in thousands)	2020		2019
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)	$	11,338	$	9,787
Implants subject to third party reimbursement sold through a specialty pharmacy (b)	3,730		2,743
Implants sold direct based on contracted rates (c)	3,109		3,226
Implants sold direct subject to third party reimbursement (d)	436		322
Biopsy kits - direct bill	466		542
Change in estimates related to prior periods (e)	1,207		(37		)
Epicel
Direct bill (hospital)	6,392		5,227
Total revenue	$	26,678	$	21,810
(a) Represents implants sold through Orsini and AllCare in both 2020 and 2019 in which such specialty pharmacies have entered into a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy's direct contracts. Also represents direct sales under a contract to the specialty distributor DMS.
(b) Represents implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The amount of reimbursement is established based on a payer or state fee schedule and/or payer history.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare in which such specialty pharmacy does not have a direct contract with the underlying payer. The initial estimate of the amount of reimbursement is established based on a payer or state fee schedule and/or payer history. The change in estimates is a result of additional information or actual cash collections received in the current period.

Schedules of concentration of risk

The table below shows the Company’s total Epicel revenue and accounts receivable balances from customers whose revenue or accounts receivable concentration is greater than 10% in any of the periods disclosed below. The Company did not have MACI revenue or accounts receivable concentrations greater than 10% in any of the periods disclosed below.

	Revenue Concentration				Accounts Receivable Concentration
	Three Months Ended March 31,				March 31,		December 31,
	2020		2019		2020		2019
Epicel	12	%	9	%	3	%	2	%